The U.S. Food and Drug Administration (FDA) has approved a new maintenance treatment for people living with extensive-stage small cell lung cancer (ES-SCLC). This approval gives patients and their care teams another option to help keep cancer under control after initial treatment.
What Was Approved
The new approval allows lurbinectedin (Zepzelca) to be used in combination with either:
- atezolizumab (Tecentriq) or
- atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza)
This combination can be used for adults with ES-SCLC whose cancer has not worsened after receiving first-line therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide.
Understanding Maintenance Therapy
Maintenance therapy is used after the first round of treatment (called induction therapy) to help prevent the cancer from coming back or progressing.
For people with small cell lung cancer, the disease often responds at first but can grow again quickly. Maintenance therapy helps to continue the benefits of initial treatment and may help patients live longer.
What the Research Found
The approval is based on results from a large clinical study called IMforte, which included 483 adults with ES-SCLC. Everyone in the trial had already completed first-line chemotherapy and immunotherapy.
- Patients were randomly assigned to receive either lurbinectedin plus atezolizumab or atezolizumab alone.
- Median overall survival: 13.2 months for the combination vs. 10.6 months with atezolizumab alone.
- Median time before the cancer grew again: 5.4 months for the combination vs. 2.1 months with atezolizumab alone.
These results show that adding lurbinectedin helped many patients live longer and kept their cancer from progressing as quickly.
Possible Side Effects
Both Zepzelca and Tecentriq can cause side effects. Not everyone experiences all side effects, and many can be managed with help from your care team.
Zepzelca (lurbinectedin):
- Lower blood cell counts, which may increase infection risk
- Liver problems
- Muscle pain or weakness (rhabdomyolysis)
- Risk to unborn babies
Tecentriq (atezolizumab) or Tecentriq Hybreza:
- Immune system reactions that may affect organs, such as the lungs, liver, intestines, or thyroid
- Infusion-related reactions
- Risk to unborn babies
Always tell your doctor right away if you experience new or worsening symptoms during treatment.
What This Means for Patients
This approval represents another step forward in improving care for people with small cell lung cancer. It provides an additional option to help manage the disease after initial therapy and offers hope for longer survival and better disease control.
Your healthcare team can help determine whether this maintenance therapy may be right for you.
Read More
Zepzelca (Lurbinectedin) in Small Cell Lung Cancer
Reference
